Preemptive use of toci has been associated with low CRS incidence and severity in patients with non-Hodgkin’s lymphoma treated with anti-CD19 CAR T-cell therapy [46,47,48]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.